Lantheus Medical Imaging helps physicians enhance patient care with a product portfolio that illuminates the heart and other organs. Our pioneering products assist physicians in the diagnosis of conditions affecting the heart, brain, lungs and other organs using echocardiography and nuclear imaging.
As a leader in the field of diagnostic imaging for 60 years, we have launched first-in-class radiopharmaceutical products including TechneLite® (Technetium Tc 99m Generator), NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection), Xenon Xe-133 Gas, Thallous Chloride Tl 201 Injection and Gallium Citrate Ga 67 Injection. The launch of the most successful radiopharmaceutical in history, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), solidified our commitment to healthcare and innovation.
In addition to our diversified portfolio of commercialized imaging agents and products, we have a strong development pipeline of internally-discovered next generation, first-in-class imaging agents, using positron emission tomography (PET), focused on enhancing current imaging modalities and fulfilling unmet diagnostic medical imaging needs.